Compare MIND & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIND | ACET |
|---|---|---|
| Founded | 1987 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 42.0M |
| IPO Year | 1997 | 2017 |
| Metric | MIND | ACET |
|---|---|---|
| Price | $4.08 | $3.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $34.83 |
| AVG Volume (30 Days) | 55.2K | ★ 296.1K |
| Earning Date | 12-08-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.77 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $42,675,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $73.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.63 | $0.46 |
| 52 Week High | $14.50 | $9.97 |
| Indicator | MIND | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 40.10 | 22.66 |
| Support Level | $3.63 | N/A |
| Resistance Level | $4.78 | $9.67 |
| Average True Range (ATR) | 0.24 | 0.42 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 6.10 | 0.71 |
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in single segment namely, Seamap which provides services and products, including engineering, repairs and software licensing, utilized in marine exploration, marine survey and maritime security for marine survey companies, seismic survey contractors, research institutes, non-military government organizations and operators of port facilities and other offshore installations. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).